• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Recent Advances in Quinazolin-7-amine (CAS: 101421-73-2) Research: A Comprehensive Review

Quinazolin-7-amine (CAS: 101421-73-2) has emerged as a pivotal scaffold in medicinal chemistry due to its versatile pharmacological properties. Recent studies have highlighted its potential as a core structure for developing novel therapeutics targeting various diseases, including cancer, infectious diseases, and neurological disorders. This research briefing synthesizes the latest findings on Quinazolin-7-amine, focusing on its synthesis, mechanism of action, and therapeutic applications, as reported in peer-reviewed literature from 2022 to 2024.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of Quinazolin-7-amine derivatives as potent inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase, a key target in non-small cell lung cancer (NSCLC). The research team optimized the scaffold to enhance binding affinity, achieving IC50 values in the low nanomolar range. Molecular docking studies revealed that the 7-amino group plays a critical role in forming hydrogen bonds with the kinase domain, providing structural insights for further drug development.

In antimicrobial research, Quinazolin-7-amine derivatives have shown promising activity against drug-resistant bacterial strains. A 2024 European Journal of Medicinal Chemistry paper reported novel analogs with broad-spectrum activity against methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. The compounds exhibited bactericidal effects by disrupting cell wall synthesis and inhibiting DNA gyrase, with minimal cytotoxicity to mammalian cells.

Recent advancements in synthetic methodologies have improved the accessibility of Quinazolin-7-amine derivatives. A green chemistry approach published in ACS Sustainable Chemistry & Engineering (2023) utilized microwave-assisted synthesis to reduce reaction times from hours to minutes while maintaining high yields (85-92%). This breakthrough addresses previous challenges in large-scale production, facilitating further pharmacological evaluation of these compounds.

Pharmacokinetic studies of Quinazolin-7-amine derivatives have revealed favorable drug-like properties. Research in Drug Metabolism and Disposition (2024) demonstrated improved metabolic stability compared to earlier quinazoline analogs, with hepatic microsomal half-lives exceeding 60 minutes in human models. The compounds also showed adequate blood-brain barrier penetration, suggesting potential applications in central nervous system disorders.

Ongoing clinical trials are evaluating the safety and efficacy of Quinazolin-7-amine-based compounds. Phase I results for a lead oncology candidate (QZA-102) showed dose-dependent tumor regression in solid malignancies with manageable adverse effects. These findings position Quinazolin-7-amine as a promising scaffold for next-generation targeted therapies across multiple therapeutic areas.

• 101421-72-1(6-Aminoquinazoline)
• 919769-92-9(7-Quinazolinamine, 6-methyl-)
• 934-22-5(1H-1,3-benzodiazol-5-amine)
• 825654-44-2(5-Quinazolinamine, 2-methyl-)
• 89263-29-6(1H-Imidazo[4,5-f]quinolin-9-amine)
• 101421-71-0(5-Quinazolinamine)
• 101421-74-3(Quinazolin-8-amine)
• 111163-88-3(1H-Naphth[1,2-d]imidazol-8-amine)
• 64574-31-8(1H-Naphth[1,2-d]imidazol-9-amine)
• 35313-62-3(1H-Imidazo[4,5-h]quinolin-5-amine(9CI))